Elevated the expression level of ARIH2 was significantly associated with reduced OS in female patients (HR=1.91, P=0.028), particularly in those of advanced age (HR=1.71, P=0.025), early tumor stages (T1&T2, HR=1.71, P=0.023), absence of lymph node metastasis (N0, HR=1.71, P=0.023), and no distant metastasis (M0, HR=1.70, P=0.018). Here, ARIH2 is linked to metastatic malignant neoplasm in the lymph nodes.